Equillium receives Australian clearance to initiate first-in-human EQ504 trial
EQ•Equillium received Australian regulatory clearance to begin its first-in-human EQ504 clinical trial and expects to start dosing by early November 2026, with topline Phase 1 data expected six months after study initiation.
1. Trial timeline
Equillium received Australian regulatory clearance to initiate its first-in-human clinical trial of EQ504. The company expects to begin dosing by early November 2026 and expects topline Phase 1 data six months after study initiation.
